

Alaska State Legislature

SENATOR PETE KELLY

SESSION:

Alaska State Capitol
Juneau, AK 99801
Phone: (907) 465-3709
Fax: (907) 465-4714



INTERIM:

1292 Sadler Way Suite 308
Fairbanks, AK 99701
Phone: (907) 451-4347
Fax: (907) 451-4348

Sectional Analysis – Senate Bill 198

“An Act relating to a study of the effectiveness and cost of providing long-acting reversible contraception to women with substance abuse disorders.”

Section 1:

(A) Directs the University of Alaska Anchorage Center for Alcohol and Addiction Studies to conduct a study to evaluate the effectiveness of providing long-acting reversible contraception (LARC) to women with substance abuse disorders who are at high risk for unintended pregnancies that may result in prenatal drug or alcohol exposure.

The study shall be done in collaboration with hospitals and health care providers in Alaska who treat women with substance abuse disorders and:

- (1) Establish an advisory council to assist with designing and implementing the study,
- (2) Evaluate best practices for treating women and children when there is a high risk of neonatal abstinence syndrome (NAS) or fetal alcohol spectrum disorders (FASD),
- (3) Facilitate a network for sharing of best practices,
- (4) Identify women and children to participate in the study on a voluntary basis,
- (5) Provide LARC to participants who are at a high risk for unintended pregnancies that may result in prenatal drug or alcohol exposure,
- (6) Evaluate the cost and effectiveness of providing LARC to reduce the occurrence of NAS and FASD,
- (7) Develop a cohort of women and children who can be evaluated in later studies regarding NAS and FASD,
- (8) Provide a data driven framework to establish a comprehensive strategy for using LARC to reduce NAS and FASD in Alaska.

(B) Directs the University to complete two interim reports by June 30 of 2019 and 2020 and a final report by June 30, 2021.

(C) Provides definitions for “fetal alcohol spectrum disorder,” “long-acting reversible contraception,” and “neonatal abstinence syndrome.”

Section 2:

Repeals Section 1 on June 30, 2021, which coincides with the date of the final report on the project